PDCD1 and neoplasm: While PD-1/CTLA-4 blocking prevents tumor growth in immunogenic tumors, triple therapy with DPP4i shrinks tumor size significantly more by recruiting eosinophils, which further solidifies the idea of T cell-eosinophil combination therapy.